The CXCR4 antagonist plerixafor is a potential therapy for myelokathexis, WHIM syndrome

Mutations in CXCR4 cause severe leukopenia in myelokathexis or WHIM syndrome. Plerixafor inhibits binding of CXCR4 to its ligand CXCL12. We investigated the effects of plerixafor (0.04 to 0.24 mg/kg) administered at 2-4 day intervals in 6 patients. Outcome measures were the patients' complete b...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Hoofdauteurs: Dale, David C., Bolyard, Audrey Anna, Kelley, Merideth L., Westrup, Ernest C., Makaryan, Vahagn, Aprikyan, Andrew, Wood, Brent, Hsu, Frank J.
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: American Society of Hematology 2011
Onderwerpen:
Clinical Trials and Observations
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC3673761/
https://ncbi.nlm.nih.gov/pubmed/21835955
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2011-06-360586
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items